Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk ... that CagriSema can improve on the efficacy of its single-agent obesity drug Wegovy (semaglutide) and help defend its obesity franchise against Eli Lilly – whose dual GIP/GLP ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...